Pharma Tech

BoomRay and Novartis sign $900m deal for radioligand therapy

Sep 23, 2026, 9:18 AM

Read Full Article → BoomRay and Novartis sign $900m deal for radioligand therapy

Translate article text

Choose a language and wait for the translated text.

BoomRay Pharmaceuticals and Novartis have signed an exclusive worldwide licence deal for an undisclosed preclinical RLT asset in a deal worth up to $900m.